Analyst Reco. Bristol-Myers Squibb Company Berne S.E.

Equities

BMY

US1101221083

End-of-day quote Berne S.E. Other stock markets 18:00:00 2024-06-20 EDT			5-day change	1st Jan Change
54.24 ^CHF	0.00%		0.00%	0.00%

06-24	Bristol Myers: accelerated approval in colorectal cancer	CF
06-22	Bristol Myers Squibb Announces U.S. FDA Accelerated Approval of KRAZATI®? in Combination with Cetuximab for Adult Patients with Previously Treated KRAS G12C-Mutated Locally Advanced or Metastatic Colorectal Cancer	CI

Analyst Reco.

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

HSBC Adjusts Price Target on Bristol-Myers Squibb to $45 From $50	05-01	MT
ANALYST RECOMMENDATIONS : Tesla, Snap, Alphabet, Microsoft, Anglo American...	04-30
Goldman Sachs Cuts Bristol-Myers Squibb's Price Target to $56 From $60	04-29	MT
Deutsche Bank Adjusts Price Target on Bristol-Myers Squibb to $53 From $55, Keeps Hold Rating	04-29	MT
Leerink Partners Cuts Price Target on Bristol-Myers Squibb to $47 From $51	04-26	MT
UBS Cuts Bristol-Myers Squibb Price Target to $47 From $52, Maintains Neutral Rating	04-26	MT
Barclays Adjusts Price Target on Bristol-Myers Squibb to $43 From $51	04-26	MT
JPMorgan Adjusts Bristol-Myers Squibb's Price Target to $60 From $65	04-26	MT
Morgan Stanley Adjusts Price Target on Bristol-Myers Squibb Company to $37 From $40	04-26	MT
Truist Cuts Price Target on Bristol-Myers Squibb to $64 From $68, Keeps Buy Rating	04-26	MT
BMO Capital Adjusts Price Target on Bristol-Myers Squibb Company to $48 From $55	04-26	MT
Jefferies Adjusts Bristol-Myers Squibb Price Target to $54 From $56, Keeps Hold Rating	04-25	MT
Cantor Fitzgerald Adjusts Price Target on Bristol-Myers Squibb to $45 From $52, Maintains Neutral Rating	04-25	MT
Cantor Fitzgerald Adjusts Bristol-Myers Squibb's Price Target to $52 From $55, Maintains Neutral Rating	04-22	MT
Wells Fargo Adjusts Bristol-Myers Squibb's Price Target to $52 From $51, Keeps Equalweight Rating	04-18	MT
Wolfe Research Adjusts Price Target on Bristol-Myers Squibb Company to $55 From $57, Outperform Rating Kept	04-15	MT
Wolfe Research Adjusts Price Target on Bristol-Myers Squibb to $55 From $57, Maintains Outperform Rating	04-15	MT
Jefferies Cuts Bristol-Myers Squibb's Price Target to $56 From $58	04-12	MT
Morgan Stanley Trims Price Target on Bristol-Myers Squibb to $40 From $41, Keeps Underweight Rating	04-09	MT
Societe Generale Downgrades Bristol-Myers Squibb to Hold From Buy, Cuts Price Target to $51 From $85	03-11	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Headlines

Christopher Boerner, CEO of Bristol-Myers: A pipeline of 16 treatments, with a focus on neuroscience and oncology

January 09, 2024 at 01:06 pm